HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope.
Daniela FeraMatthew S LeeKevin WieheR Ryan MeyerhoffAlessandro PiaiMattia BonsignoriBaptiste AussedatWilliam E WalkowiczTherese TonJeffrey O ZhouSamuel DanishefskyBarton F HaynesStephen C HarrisonPublished in: Nature communications (2018)
HIV-1 envelope (Env) mimetics are candidate components of prophylactic vaccines and potential therapeutics. Here we use a synthetic V3-glycopeptide ("Man9-V3") for structural studies of an HIV Env third variable loop (V3)-glycan directed, broadly neutralizing antibody (bnAb) lineage ("DH270"), to visualize the epitope on Env and to study how affinity maturation of the lineage proceeded. Unlike many previous V3 mimetics, Man9-V3 encompasses two key features of the V3 region recognized by V3-glycan bnAbs-the conserved GDIR motif and the N332 glycan. In our structure of an antibody fragment of a lineage member, DH270.6, in complex with the V3 glycopeptide, the conformation of the antibody-bound glycopeptide conforms closely to that of the corresponding segment in an intact HIV-1 Env trimer. An additional structure identifies roles for two critical mutations in the development of breadth. The results suggest a strategy for use of a V3 glycopeptide as a vaccine immunogen.
Keyphrases
- antiretroviral therapy
- hiv positive
- hiv infected
- hiv testing
- human immunodeficiency virus
- hepatitis c virus
- hiv aids
- men who have sex with men
- south africa
- transcription factor
- genome wide
- dengue virus
- gene expression
- small molecule
- dna methylation
- cell surface
- risk assessment
- cell fate
- mass spectrometry
- molecular dynamics simulations
- human health